{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:55:38Z","timestamp":1778151338376,"version":"3.51.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s11864-019-0623-8","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T12:05:20Z","timestamp":1552565120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Role of Bisphosphonates in Breast Cancer Therapy"],"prefix":"10.1007","volume":"20","author":[{"given":"Hadar","family":"Goldvaser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eitan","family":"Amir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"issue":"12","key":"623_CR1","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1002\/1097-0142(19861215)58:12<2589::AID-CNCR2820581206>3.0.CO;2-O","volume":"58","author":"V Scheid","year":"1986","unstructured":"Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer. 1986;58(12):2589\u201393.","journal-title":"Cancer."},{"issue":"12","key":"623_CR2","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1172\/JCI118722","volume":"97","author":"GA Rodan","year":"1996","unstructured":"Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest. 1996;97(12):2692\u20136.","journal-title":"J Clin Invest."},{"issue":"10","key":"623_CR3","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","volume":"10","author":"DE Hughes","year":"1995","unstructured":"Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10(10):1478.","journal-title":"J Bone Miner Res."},{"issue":"6","key":"623_CR4","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","volume":"16","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998;16(6):2038\u201344.","journal-title":"J Clin Oncol."},{"issue":"3","key":"623_CR5","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","volume":"17","author":"RL Theriault","year":"1999","unstructured":"Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gl\u00fcck S, Stewart JF, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999;17(3):846\u201354.","journal-title":"J Clin Oncol."},{"issue":"1","key":"623_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","volume":"11","author":"AH Paterson","year":"1993","unstructured":"Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11(1):59\u201365.","journal-title":"J Clin Oncol."},{"issue":"6","key":"623_CR7","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","volume":"90","author":"JJ Body","year":"2004","unstructured":"Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004;90(6):1133\u20137.","journal-title":"Br J Cancer."},{"issue":"1","key":"623_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cncr.11892","volume":"100","author":"LS Rosen","year":"2004","unstructured":"Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100(1):36\u201343.","journal-title":"Cancer."},{"issue":"5","key":"623_CR9","first-page":"377","volume":"7","author":"LS Rosen","year":"2001","unstructured":"Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7(5):377\u201387.","journal-title":"Cancer J."},{"issue":"2","key":"623_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","volume":"19","author":"P Major","year":"2001","unstructured":"Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19(2):558\u201367.","journal-title":"J Clin Oncol."},{"issue":"1","key":"623_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","volume":"15","author":"P Barrett-Lee","year":"2014","unstructured":"Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. Lancet Oncol. 2014;15(1):114\u201322.","journal-title":"Lancet Oncol."},{"issue":"35","key":"623_CR12","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132\u20139.","journal-title":"J Clin Oncol."},{"key":"623_CR13","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.1158\/1078-0432.CCR-11-3310","volume":"18","author":"M Martin","year":"2012","unstructured":"Martin M, Bell R, Bourgeois H, et al. Bone-related complications and quality of life in advanced breast cancer: Results from a randomized phase III trial of denosumab versus zoledronic acid. Clin Cancer Res. 2012;18:4841\u20139.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"623_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJM199808063390601","volume":"339","author":"IJ Diel","year":"1998","unstructured":"Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339(6):357\u201363.","journal-title":"N Engl J Med."},{"issue":"12","key":"623_CR15","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","volume":"19","author":"IJ Diel","year":"2008","unstructured":"Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol. 2008;19(12):2007\u201311.","journal-title":"Ann Oncol."},{"issue":"2","key":"623_CR16","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1186\/bcr1384","volume":"8","author":"T Powles","year":"2006","unstructured":"Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 2006;8(2):R13.","journal-title":"Breast Cancer Res."},{"issue":"7","key":"623_CR17","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","volume":"13","author":"AH Paterson","year":"2012","unstructured":"Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol. 2012;13(7):734\u201342.","journal-title":"Lancet Oncol."},{"issue":"28","key":"623_CR18","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1200\/JCO.2012.47.2167","volume":"31","author":"G Minckwitz von","year":"2013","unstructured":"von Minckwitz G, M\u00f6bus V, Schneeweiss A, Huober J, Thomssen C, Untch M, et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer. J Clin Oncol. 2013;31(28):3531\u20139.","journal-title":"J Clin Oncol."},{"issue":"4","key":"623_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1080\/02841860801964988","volume":"47","author":"B Kristensen","year":"2008","unstructured":"Kristensen B, Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol. 2008;47(4):740\u20136.","journal-title":"Acta Oncol."},{"issue":"9","key":"623_CR20","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","volume":"15","author":"R Coleman","year":"2014","unstructured":"\u2022 Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial. Lancet Oncol. 2014;15(9):997\u20131006 First randomized trial to identify the benefit of bisphosphonates in early-stage breast cancer as being limited to postmenopausal women.","journal-title":"Lancet Oncol"},{"issue":"2","key":"623_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/annonc\/mdu544","volume":"26","author":"M Gnant","year":"2015","unstructured":"Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol. 2015;26(2):313\u201320.","journal-title":"Ann Oncol."},{"key":"623_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2016.05.015","volume":"64","author":"G Minckwitz von","year":"2016","unstructured":"von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm DM, et al. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - the Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36\/ABCSG 29). Eur J Cancer. 2016;64:12\u201321.","journal-title":"Eur J Cancer."},{"key":"623_CR23","doi-asserted-by":"crossref","unstructured":"Jani W, Friedl T, Fehm T, Mueller V, Lichtenegger W, Blohmer J, et al. Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: phase III data from the SUCCESS A study. Presented at the San Antonio Breast Cancer Symposium 2017, #GS01.","DOI":"10.1158\/1538-7445.SABCS17-GS1-06"},{"issue":"15_suppl","key":"623_CR24","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1200\/jco.2014.32.15_suppl.558","volume":"32","author":"Julie Gralow","year":"2014","unstructured":"Gralow J, Barlow WE, Paterson AHG, et al. SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: comparison of toxicities and patient-stated preference for oral versus intravenous delivery. J Clin Oncol 32, 2014 (abstr 558).","journal-title":"Journal of Clinical Oncology"},{"issue":"15_suppl","key":"623_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1200\/jco.2015.33.15_suppl.503","volume":"33","author":"Julie Gralow","year":"2015","unstructured":"Gralow J, Barlow WE, Paterson AHG, et al. Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG\/Alliance\/ECOG-ACRIN\/NCIC Clinical Trials Group\/NRG Oncology Study S0307. J Clin Oncol 33, 2015 (abstr 503).","journal-title":"Journal of Clinical Oncology"},{"key":"623_CR26","first-page":"CD003474","volume":"10","author":"B O\u2019Carrigan","year":"2017","unstructured":"\u2022\u2022 O\u2019Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017;10:CD003474 Meta-analysis of randomized trials of bisphosphonates for both early-stage and metastatic breast cancer.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"623_CR27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.clon.2013.03.003","volume":"25","author":"M Poon","year":"2013","unstructured":"Poon M, Zeng L, Zhang L, Lam H, Emmenegger U, Wong E, et al. Incidence of skeletal-related events over time from solid tumour bone metastases reported in randomised trials using bone-modifying agents. Clin Oncol (R Coll Radiol). 2013;25(7):435\u201344.","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"623_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ejca.2016.05.014","volume":"63","author":"S G\u00f3mez Garc\u00eda","year":"2016","unstructured":"G\u00f3mez Garc\u00eda S, Clemons M, Amir E. Rethinking end-points for bone-targeted therapy in advanced cancer. Eur J Cancer. 2016;63:105\u20139.","journal-title":"Eur J Cancer."},{"issue":"5","key":"623_CR29","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/jbmr.5650090521","volume":"9","author":"JR Green","year":"1994","unstructured":"Green JR, M\u00fcller K, Jaeggi KA. Preclinical pharmacology of CGP 42\u2019446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9(5):745\u201351.","journal-title":"J Bone Miner Res."},{"issue":"5","key":"623_CR30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/annonc\/mdh173","volume":"15","author":"D Tripathy","year":"2004","unstructured":"Tripathy D, Lichinitzer M, Lazarev A, MacLachlan SA, Apffelstaedt J, Budde M, et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol. 2004;15(5):743\u201350.","journal-title":"Ann Oncol."},{"key":"623_CR31","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","volume":"29","author":"CH Poznak Van","year":"2011","unstructured":"Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29:1221\u20137.","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"623_CR32","doi-asserted-by":"crossref","first-page":"9501","DOI":"10.1200\/jco.2015.33.15_suppl.9501","volume":"33","author":"AL Himelstein","year":"2015","unstructured":"Himelstein AL, Qin R, Novotny PJ, Seisler DK, Khatcheressian JL, Roberts JD, et al. CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. J Clin Oncol. 2015;33(15 Suppl):9501 0732\u2013183X.","journal-title":"J Clin Oncol"},{"issue":"5 Suppl","key":"623_CR33","doi-asserted-by":"publisher","first-page":"LBA9500","DOI":"10.1200\/jco.2014.32.15_suppl.lba9500","volume":"32","author":"GN Hortobagyi","year":"2014","unstructured":"Hortobagyi GN, Lipton A, Chew HK, et al. Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE-2 trial. J Clin Oncol. 2014;32(5 Suppl):LBA9500.","journal-title":"J Clin Oncol"},{"issue":"7","key":"623_CR34","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","volume":"14","author":"D Amadori","year":"2013","unstructured":"Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol. 2013;14(7):663\u201370.","journal-title":"Lancet Oncol."},{"issue":"16","key":"623_CR35","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082\u201392.","journal-title":"Eur J Cancer."},{"key":"623_CR36","unstructured":"Amgen Canada Inc. XGEVA\u00ae product monograph. Mississauga, Ontario; 14 October 2011."},{"issue":"35","key":"623_CR37","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1200\/JCO.2017.73.7437","volume":"35","author":"CL Shapiro","year":"2017","unstructured":"\u2022 Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, et al. Cost-effectiveness analysis of monthly zoledronic acid, zoledronic acid every 3 months, and monthly denosumab in women with breast cancer and skeletal metastases: CALGB 70604 (Alliance). J Clin Oncol. 2017;35(35):3949\u201355 Robust cost-effectiveness analysis for different therapeutic options for bone-targeted therapy in metastatic breast cancer.","journal-title":"J Clin Oncol"},{"key":"623_CR38","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","volume":"35","author":"C Poznak Van","year":"2017","unstructured":"\u2022\u2022 Van Poznak C, Somerfield MR, Barlow WE, et al. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline update. J Clin Oncol. 2017;35:3978 Important North American practice guideline for the use of bone-targeted therapy in metastatic breast cancer.","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"623_CR39","doi-asserted-by":"publisher","first-page":"iii124","DOI":"10.1093\/annonc\/mdu103","volume":"25","author":"R Coleman","year":"2014","unstructured":"Coleman R, Body JJ, Aapro M, et al. Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2014;25(Suppl 3):iii124.","journal-title":"Ann Oncol"},{"key":"623_CR40","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/annonc\/mdu385","volume":"25","author":"F Cardoso","year":"2014","unstructured":"Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)\u2020. Ann Oncol. 2014;25:1871.","journal-title":"Ann Oncol"},{"key":"623_CR41","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/2193-1801-3-328","volume":"3","author":"D L\u00fcftner","year":"2014","unstructured":"L\u00fcftner D, Lorusso V, Duran I, Hechmati G, Garzon-Rodriguez C, Ashcroft J, et al. Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study. Springerplus. 2014;3:328.","journal-title":"Springerplus."},{"issue":"6","key":"623_CR42","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1093\/annonc\/mdv148","volume":"26","author":"AD Hartkopf","year":"2015","unstructured":"Hartkopf AD, Wallwiener M, Fehm TN, Hahn M, Walter CB, Gruber I, et al. Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse. Ann Oncol. 2015;26(6):1155\u201360.","journal-title":"Ann Oncol."},{"key":"623_CR43","doi-asserted-by":"publisher","first-page":"11089","DOI":"10.1158\/0008-5472.CAN-06-2407","volume":"66","author":"RN Kaplan","year":"2006","unstructured":"Kaplan RN, Rafii S, Lyden D. Preparing the \u2018soil\u2019: the premetastatic niche. Cancer Res. 2006;66:11089\u201393.","journal-title":"Cancer Res."},{"key":"623_CR44","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","volume":"11","author":"KN Weilbaecher","year":"2011","unstructured":"Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011;11:411\u201325.","journal-title":"Nat Rev Cancer."},{"key":"623_CR45","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655\u201364.","journal-title":"N Engl J Med"},{"key":"623_CR46","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.bbrc.2004.11.070","volume":"328","author":"T Yoneda","year":"2005","unstructured":"Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem. Biophys. Res. Commun. 2005;328:679\u201387.","journal-title":"Biochem. Biophys. Res. Commun"},{"issue":"4","key":"623_CR47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jbo.2013.06.001","volume":"2","author":"K Russell","year":"2013","unstructured":"Russell K, Amir E, Paterson A, Josse R, Addison C, Kuchuk I, et al. Does estrogen play a role in response to adjuvant bone-targeted therapies? J Bone Oncol. 2013;2(4):167\u201373.","journal-title":"J Bone Oncol"},{"issue":"10001","key":"623_CR48","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2015","unstructured":"\u2022\u2022 Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001):1353\u201361 Individual patient meta-analysis of trials exploring bisphosphonates in early-stage breast cancer. Confirmed that benefit was seen only in postmenopausal women.","journal-title":"Lancet"},{"issue":"21","key":"623_CR49","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1200\/JCO.2012.46.4792","volume":"31","author":"EJ Rathbone","year":"2013","unstructured":"Rathbone EJ, Brown JE, Marshall HC, Collinson M, Liversedge V, Murden GA, et al. Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01\/04). J Clin Oncol. 2013;31(21):2685\u201391.","journal-title":"J Clin Oncol."},{"issue":"8","key":"623_CR50","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","volume":"28","author":"G Curigliano","year":"2017","unstructured":"Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017;28(8):1700\u201312.","journal-title":"Ann Oncol."},{"issue":"3","key":"623_CR51","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/annonc\/mdv617","volume":"27","author":"P Hadji","year":"2016","unstructured":"Hadji P, Coleman RE, Wilson C, Cl\u00e9zardin P, Aapro M, et al. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Ann Oncol. 2016;27(3):379\u201390.","journal-title":"Ann Oncol."},{"issue":"9992","key":"623_CR52","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9992):433\u201343.","journal-title":"Lancet."},{"key":"623_CR53","doi-asserted-by":"publisher","first-page":"ASCO #500","DOI":"10.1200\/JCO.2018.36.15_suppl.500","volume":"36S","author":"M Gnant","year":"2018","unstructured":"Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in early breast cancer: disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. J Clin Oncol. 2018;36S:ASCO #500.","journal-title":"J Clin Oncol"},{"key":"623_CR54","doi-asserted-by":"publisher","first-page":"ASCO #501","DOI":"10.1200\/JCO.2018.36.15_suppl.501","volume":"36S","author":"RE Coleman","year":"2018","unstructured":"Coleman RE, Finkelstein D, Barrios CH, et al. Adjuvant denosumab in early breast cancer: first results from the international multicenter randomized phase III placebo controlled D-CARE study. J Clin Oncol. 2018;36S:ASCO #501.","journal-title":"J Clin Oncol"},{"issue":"17","key":"623_CR55","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1093\/jnci\/djr242","volume":"103","author":"E Amir","year":"2011","unstructured":"Amir E, Seruga B, Niraula S, Carlsson L, Oca\u00f1a A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011 Sep 7;103(17):1299\u2013309.","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"623_CR56","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/jnci\/djx141","volume":"110","author":"Hadar Goldvaser","year":"2017","unstructured":"Goldvaser H, Barnes TA, \u0160eruga B, Cescon DW, Oca\u00f1a A, Ribnikar D, Amir E. Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110(1):djx141.","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"30","key":"623_CR57","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1200\/JCO.2012.42.2097","volume":"30","author":"MB Lustberg","year":"2012","unstructured":"Lustberg MB, Reinbolt RE, Shapiro CL. Bone health in adult cancer survivorship. J Clin Oncol. 2012;30(30):3665\u201374.","journal-title":"J Clin Oncol"},{"issue":"2","key":"623_CR58","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24(2):398\u2013405.","journal-title":"Ann Oncol."},{"issue":"2","key":"623_CR59","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","volume":"9","author":"AM Brufsky","year":"2009","unstructured":"Brufsky AM, Bosserman LD, Caradonna RR, Haley BB, Jones CM, Moore HC, et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 2009;9(2):77\u201385.","journal-title":"Clin Breast Cancer."},{"issue":"1","key":"623_CR60","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.clbc.2011.08.002","volume":"12","author":"A Llombart","year":"2012","unstructured":"Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, et al. Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer. 2012;12(1):40\u20138.","journal-title":"Clin Breast Cancer."},{"key":"623_CR61","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337\u201342.","journal-title":"Nature."},{"issue":"1","key":"623_CR62","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153\u201361.","journal-title":"J Bone Miner Res."},{"key":"623_CR63","unstructured":"http:\/\/www.bccancer.bc.ca\/health-professionals\/clinical-resources\/cancer-drug-manual\n                      \n                    , accessed August 2018."},{"key":"623_CR64","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1210\/edrv.23.3.0465","volume":"23","author":"BL Riggs","year":"2002","unstructured":"Riggs BL, Khosla S, Melton LJ III. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23:279\u2013302.","journal-title":"Endocr Rev"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0623-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11864-019-0623-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-019-0623-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:42:38Z","timestamp":1584060158000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11864-019-0623-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["623"],"URL":"https:\/\/doi.org\/10.1007\/s11864-019-0623-8","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"assertion":[{"value":"14 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Hadar Goldvaser declares that she has no conflict of interest.Eitan Amir has received compensation from Genentech\/Roche for the provision of expert testimony and from Apobiologix Agendia and Myriad Genetics for service as a consultant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"26"}}